V.L. Perrin

559 total citations
11 papers, 425 citations indexed

About

V.L. Perrin is a scholar working on Physiology, Psychiatry and Mental health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, V.L. Perrin has authored 11 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Physiology, 5 papers in Psychiatry and Mental health and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in V.L. Perrin's work include Migraine and Headache Studies (5 papers), Inhalation and Respiratory Drug Delivery (4 papers) and Asthma and respiratory diseases (4 papers). V.L. Perrin is often cited by papers focused on Migraine and Headache Studies (5 papers), Inhalation and Respiratory Drug Delivery (4 papers) and Asthma and respiratory diseases (4 papers). V.L. Perrin collaborates with scholars based in United Kingdom, Germany and United States. V.L. Perrin's co-authors include Α. Doenicke, Janusz Milanowski, Martti Färkkilâ, Peer Tfelt‐Hansen, Jeremy Hugh Baron, M.G.L. Hertog, Ian Farmer, Anthony J. Frew, Stephen J. Langley and Jennie Brand‐Miller and has published in prestigious journals such as The Lancet, Clinical Pharmacokinetics and Cephalalgia.

In The Last Decade

V.L. Perrin

11 papers receiving 388 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V.L. Perrin United Kingdom	9	203	155	111	72	67	11	425
P. R. Saxena Netherlands	11	87 0.4×	127 0.8×	58 0.5×	82 1.1×	46 0.7×	16	338
Ana Cristina Martı́nez Spain	16	139 0.7×	194 1.3×	29 0.3×	110 1.5×	46 0.7×	42	656
Irene Grazioli Italy	13	147 0.7×	131 0.8×	84 0.8×	30 0.4×	19 0.3×	18	404
E Vincenti Italy	12	36 0.2×	118 0.8×	76 0.7×	147 2.0×	101 1.5×	44	539
Alan J. Tuchman United States	11	50 0.2×	83 0.5×	50 0.5×	52 0.7×	21 0.3×	22	447
Herbert R. Henney United States	14	89 0.4×	29 0.2×	200 1.8×	127 1.8×	22 0.3×	30	657
Bark-Jang Byun South Korea	7	98 0.5×	51 0.3×	69 0.6×	57 0.8×	12 0.2×	7	358
S. D. Gergis United States	15	75 0.4×	48 0.3×	19 0.2×	128 1.8×	50 0.7×	45	584
D. Varonos Greece	15	35 0.2×	75 0.5×	129 1.2×	268 3.7×	33 0.5×	46	598
V. V. Myllyl� Finland	9	215 1.1×	32 0.2×	16 0.1×	26 0.4×	14 0.2×	11	507

Countries citing papers authored by V.L. Perrin

Since Specialization

Citations

This map shows the geographic impact of V.L. Perrin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V.L. Perrin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V.L. Perrin more than expected).

Fields of papers citing papers by V.L. Perrin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V.L. Perrin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V.L. Perrin. The network helps show where V.L. Perrin may publish in the future.

Co-authorship network of co-authors of V.L. Perrin

This figure shows the co-authorship network connecting the top 25 collaborators of V.L. Perrin. A scholar is included among the top collaborators of V.L. Perrin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V.L. Perrin. V.L. Perrin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Frew, Anthony J., Stephen J. Langley, V.L. Perrin, & M.G.L. Hertog. (2002). Effects of 4-week treatment with low-dose budesonide (100 μg BID) from a novel inhaler AirmaxTM and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma. Respiratory Medicine. 96(7). 542–547. 10 indexed citations

Perrin, V.L., et al.. (2002). Bronchodilating effects of salbutamol from a novel inhaler AirmaxTM. Respiratory Medicine. 96(7). 493–498. 5 indexed citations

Farmer, Ian, et al.. (2000). Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the EasibreatheTMinhaler for the treatment of paediatric asthma. Respiratory Medicine. 94(1). 57–63. 15 indexed citations

Milanowski, Janusz, et al.. (1999). Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma. Respiratory Medicine. 93(4). 245–251. 20 indexed citations

Perrin, V.L., et al.. (1989). Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine.. PubMed. 9 Suppl 9. 63–72. 41 indexed citations

Doenicke, Α., et al.. (1988). 新規5-HT 1 様受容体アゴニストGR43175の重症片頭痛に対する急性治療効果. The Lancet. 1(8598). 1309–1311. 89 indexed citations

Doenicke, Α., et al.. (1988). POSSIBLE BENEFIT OF GR43175, A NOVEL 5-HT1-LIKE RECEPTOR AGONIST, FOR THE ACUTE TREATMENT OF SEVERE MIGRAINE. The Lancet. 331(8598). 1309–1311. 143 indexed citations

Doenicke, Α., et al.. (1987). Initial Clinical Study Of Ah25086B (5-Ht₁-Like Agonist) In The Acute Treatment Of Migraine. Cephalalgia. 7(6_suppl). 438–439. 14 indexed citations

Brand‐Miller, Jennie, et al.. (1987). Placebo Controlled Study Of A Selective 5-Th₁-Like Agonist, Ah25086B, In Relief Of Acute Migraine. Cephalalgia. 7(6_suppl). 402–403. 8 indexed citations

10.

Perrin, V.L.. (1985). Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster Headache. Clinical Pharmacokinetics. 10(4). 334–352. 61 indexed citations

11.

Baron, Jeremy Hugh, et al.. (1983). Gastric Ulcer Healing with Ranitidine and Cimetidine. Scandinavian Journal of Gastroenterology. 18(7). 973–976. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact